US stock futures muted with Jackson Hole, retail earnings on tap
PharmAthene Inc (NASDAQ:ALT) shares tumbled to a 52-week low of $5.1, reflecting a period of significant pressure for the biodefense company with a market capitalization of $410 million. The stock’s decline has caught the attention of analysts, who maintain a consensus recommendation of 1.7 (Strong Buy), with price targets ranging from $12 to $28. Over the past year, the stock has experienced a substantial decline, with the 1-year change data showing a decrease of nearly 48%. This downturn has been a cause for concern among investors, as the company grapples with market challenges that have eroded shareholder value. The 52-week low serves as a critical indicator of the current sentiment surrounding PharmAthene’s financial health and future prospects. According to InvestingPro analysis, the company currently trades near its Fair Value, with 12 additional exclusive ProTips available to subscribers, including detailed insights into the company’s financial health and market position.
In other recent news, Altimmune Inc. reported its fourth-quarter 2024 earnings, slightly surpassing EPS forecasts with a reported EPS of -0.33 compared to the expected -0.34. However, the company’s revenue fell significantly short of expectations, with actual revenue reported at $5 million against a forecast of $714 million. Despite this revenue shortfall, analysts have maintained a positive outlook on the company’s stock. Stifel reiterated a Buy rating with an $18 price target, while Citizens JMP maintained a Market Outperform rating with a $25 target, both citing optimism around Altimmune’s drug pemvidutide and its potential applications.
H.C. Wainwright also reaffirmed a Buy rating with a $12 price target, pointing to several anticipated catalysts in the coming year that could enhance the stock’s value. These include upcoming trial results and the expansion of pemvidutide into additional metabolic indications. The drug has shown promise in improving liver fat reduction, fibrosis, and achieving meaningful weight loss, which could position it as a significant player in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and related disorders.
Altimmune’s strong cash position of $132 million is expected to support its operations into the second half of 2026, facilitating the continuation of its clinical trials and other strategic initiatives. The company is preparing for the Phase 2b trial results of pemvidutide, expected in the second quarter of 2025, which could be pivotal in advancing to a Phase 3 program. Analysts are particularly optimistic about the drug’s potential to meet critical endpoints, which could lead to expanded market opportunities and partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.